Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323353350> ?p ?o ?g. }
- W4323353350 endingPage "462" @default.
- W4323353350 startingPage "456" @default.
- W4323353350 abstract "COVID-19 adversely affects individuals with cancer. Several studies have found that seroconversion rates among patients with hematologic malignancies are suboptimal when compared to patients without cancer. Patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) are immunocompromised due to impaired humoral and cellular immunity in addition to prescribed immunosuppressive therapy. Chimeric antigen receptor T-cell (CAR T) therapy is now widely used for NHL and MM, but little is known about seroconversion rates after COVID-19 vaccination among these populations. We evaluated SARS-CoV-2 spike-binding IgG antibody levels following COVID-19 vaccination among NHL and MM CAR T therapy recipients. Out of 104 CAR T infusions, 19 patients developed known COVID-19 infection post-CAR T. We tested 17 patients that received CAR T for antibody spike titers post COVID-19 vaccination, only 29 % (n = 5) were able to mount a clinically relevant antibody response (>250 IU/mL)." @default.
- W4323353350 created "2023-03-08" @default.
- W4323353350 creator A5001453763 @default.
- W4323353350 creator A5003015868 @default.
- W4323353350 creator A5003238099 @default.
- W4323353350 creator A5004436275 @default.
- W4323353350 creator A5007747233 @default.
- W4323353350 creator A5008583422 @default.
- W4323353350 creator A5013814515 @default.
- W4323353350 creator A5017327825 @default.
- W4323353350 creator A5026574827 @default.
- W4323353350 creator A5027394636 @default.
- W4323353350 creator A5027814648 @default.
- W4323353350 creator A5033220547 @default.
- W4323353350 creator A5036373597 @default.
- W4323353350 creator A5037629427 @default.
- W4323353350 creator A5038008601 @default.
- W4323353350 creator A5048693913 @default.
- W4323353350 creator A5048695526 @default.
- W4323353350 creator A5051399808 @default.
- W4323353350 creator A5056239333 @default.
- W4323353350 creator A5056260546 @default.
- W4323353350 creator A5057941081 @default.
- W4323353350 creator A5059729547 @default.
- W4323353350 creator A5060271747 @default.
- W4323353350 creator A5061713890 @default.
- W4323353350 creator A5061845933 @default.
- W4323353350 creator A5069952110 @default.
- W4323353350 creator A5072569354 @default.
- W4323353350 creator A5073854104 @default.
- W4323353350 creator A5074505099 @default.
- W4323353350 creator A5085182402 @default.
- W4323353350 creator A5087950597 @default.
- W4323353350 creator A5089032046 @default.
- W4323353350 creator A5089945401 @default.
- W4323353350 creator A5090442154 @default.
- W4323353350 creator A5090694142 @default.
- W4323353350 date "2023-06-01" @default.
- W4323353350 modified "2023-10-13" @default.
- W4323353350 title "Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma" @default.
- W4323353350 cites W3097738396 @default.
- W4323353350 cites W3117702394 @default.
- W4323353350 cites W3120738879 @default.
- W4323353350 cites W3156866359 @default.
- W4323353350 cites W3165224470 @default.
- W4323353350 cites W3173150656 @default.
- W4323353350 cites W3174178131 @default.
- W4323353350 cites W3175432865 @default.
- W4323353350 cites W3180610917 @default.
- W4323353350 cites W3183558279 @default.
- W4323353350 cites W3190264333 @default.
- W4323353350 cites W3192156468 @default.
- W4323353350 cites W3197323998 @default.
- W4323353350 cites W3200273570 @default.
- W4323353350 cites W3202498320 @default.
- W4323353350 cites W3217284394 @default.
- W4323353350 cites W3217661335 @default.
- W4323353350 cites W4200574310 @default.
- W4323353350 cites W4206991218 @default.
- W4323353350 cites W4214646636 @default.
- W4323353350 cites W4226094308 @default.
- W4323353350 cites W4285008916 @default.
- W4323353350 cites W4293795301 @default.
- W4323353350 doi "https://doi.org/10.1016/j.clml.2023.03.002" @default.
- W4323353350 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37003846" @default.
- W4323353350 hasPublicationYear "2023" @default.
- W4323353350 type Work @default.
- W4323353350 citedByCount "5" @default.
- W4323353350 countsByYear W43233533502023 @default.
- W4323353350 crossrefType "journal-article" @default.
- W4323353350 hasAuthorship W4323353350A5001453763 @default.
- W4323353350 hasAuthorship W4323353350A5003015868 @default.
- W4323353350 hasAuthorship W4323353350A5003238099 @default.
- W4323353350 hasAuthorship W4323353350A5004436275 @default.
- W4323353350 hasAuthorship W4323353350A5007747233 @default.
- W4323353350 hasAuthorship W4323353350A5008583422 @default.
- W4323353350 hasAuthorship W4323353350A5013814515 @default.
- W4323353350 hasAuthorship W4323353350A5017327825 @default.
- W4323353350 hasAuthorship W4323353350A5026574827 @default.
- W4323353350 hasAuthorship W4323353350A5027394636 @default.
- W4323353350 hasAuthorship W4323353350A5027814648 @default.
- W4323353350 hasAuthorship W4323353350A5033220547 @default.
- W4323353350 hasAuthorship W4323353350A5036373597 @default.
- W4323353350 hasAuthorship W4323353350A5037629427 @default.
- W4323353350 hasAuthorship W4323353350A5038008601 @default.
- W4323353350 hasAuthorship W4323353350A5048693913 @default.
- W4323353350 hasAuthorship W4323353350A5048695526 @default.
- W4323353350 hasAuthorship W4323353350A5051399808 @default.
- W4323353350 hasAuthorship W4323353350A5056239333 @default.
- W4323353350 hasAuthorship W4323353350A5056260546 @default.
- W4323353350 hasAuthorship W4323353350A5057941081 @default.
- W4323353350 hasAuthorship W4323353350A5059729547 @default.
- W4323353350 hasAuthorship W4323353350A5060271747 @default.
- W4323353350 hasAuthorship W4323353350A5061713890 @default.
- W4323353350 hasAuthorship W4323353350A5061845933 @default.
- W4323353350 hasAuthorship W4323353350A5069952110 @default.
- W4323353350 hasAuthorship W4323353350A5072569354 @default.
- W4323353350 hasAuthorship W4323353350A5073854104 @default.